Title:

Modeling the Heterogeneity and Trajectories of Cognitive Dysfunction in Parkinson's Disease Using Partially Ordered Set Models.

Authors:

Cole Zweber, MMS[1], Brenna Cholerton, PhD[2], Abigail Ryan, PhD[3], Cyrus Zabetian, MD[4], Rebecca Miller, PhD[5], Vivikta Iyer, MD[6], Amie Hiller, MD[7], Satya Sahoo, PhD[8], Curtis Tatsuoka, PhD[9*], Deepak K. Gupta, MD[6,10*]

[1]Office of Medical Student Education, College of Medicine, University of Vermont, Burlington, USA

[2]Department of Pathology, School of Medicine, Stanford University, Stanford, USA

[3]Department of Psychiatry, University of Vermont Medical Center, Burlington, USA

4Geriatric Research Education and Clinical Center, and Parkinson's Disease Research Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA

[4]Department of Neurology, School of Medicine, University of Washington and Seattle Veteran Affairs Medical Center, Seattle, USA

[5]Department of Psychiatry, School of Medicine, Yale University, New Haven, USA

[6]Department of Neurological Sciences, College of Medicine, University of Vermont, Burlington, USA

[7]Department of Neurology, Oregon Health & Sciences University and Portland Veteran Affairs Medical Center, Portland, USA

[8]Department of Population & Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, USA

[9]Department of Epidemiology & Public Health, School of Medicine, University of Maryland, Baltimore, USA

[10]Clinical Informatics, University of Vermont Health Network Medical Group, Burlington, USA

* Corresponding Authors:

Deepak K. Gupta, MD, MS, (drdkgupta@gmail.com), 802-489-6886, 1 South Prospect Street, Arnold, Level 2, Burlington, VT 05401-5505

Curtis Tatsuoka, PhD, (ctatsuoka@som.umaryland.edu), 410-706-8506, 655 West Baltimore Street, Baltimore, Maryland 21201

Word Count: 3813

Abstract

IMPORTANCE: Cognitive dysfunction is a common and burdensome non-motor feature of Parkinson's disease (PD). Since the heterogeneity and trajectories are not fully captured by current binary classification schemes of mild cognitive impairment (MCI) and dementia, there is a critical need to apply novel approaches for studying cognitive dysfunction in PD.

OBJECTIVES: 1. To review MCI and dementia classification schemes and describe the Partially Ordered Set (POSET) model for studying cognitive dysfunction in PD. 2. To illustrate application of POSET modeling for classifying cognitive dysfunction in PD using the Parkinson's Progression Marker Initiative (PPMI) data.

DESIGN: Based on neuropsychologists' expert opinion, we define and map five domains of cognitive performance (*Attention, Visuospatial Judgement, Executive Functioning, Working Memory, Episodic Memory*) onto nine neuropsychological measures available in the PPMI data and then use POSET modeling to calculate corresponding Cognitive Performance Scores (CPS) as posterior probabilities of a patient's level of performance. We then compare differences and trajectories of median value of CPS in PD patients with or without cognitive dysfunction at year 3 in a study cohort of 264 patients (selected from original cohort of 423 patients, after removing patients with MCI or dementia at baseline or missing relevant data at any of four annual visits from baseline to year 3).

EXPOSURE: Relatively lower value of CPS at baseline.

MAIN OUTCOME MEASURE: Cognitive dysfunction at year 3 (yes or no), which is defined as either MCI or dementia per assessment by the site investigator in the PPMI study.

RESULTS: The mean age was 61.16 years and there were 67% males in the study cohort. PD patients with cognitive dysfunction at year 3 (n=56, 21.2%) had significantly lower ($p < 0.05$) median values for all CPS at all four visits (except Episodic Memory at baseline) and exhibited distinct median trajectories over all four years. Logistic regression demonstrated that two baseline CPS (Attention and Visuospatial Judgement) were significant predictors for development of cognitive dysfunction at year 3.

CONCLUSIONS: It is feasible to apply POSET models-based approach for delineating the heterogeneity and trajectories of cognitive dysfunction in PD.

Keywords: Parkinson Disease, Cognitive Dysfunction, Neuropsychological Tests, Informatics

Key Points

Question: Is it feasible to apply Partially Ordered Set (POSET) models for studying cognitive dysfunction in Parkinson's disease (PD) to address limitations conventional binary classification of mild cognitive impairment (MCI) and dementia?

Findings: In this cohort study of 264 PD patients from the Parkinson's Progression Marker Initiative (PPMI) data, trajectories of POSET models-based Cognitive Performance Scores (CPS) were consistently and substantially lower in patients with cognitive dysfunction (MCI or dementia) at year 3.

Meaning: The POSET models-based approach is feasible for delineating heterogeneity and trajectories of cognitive dysfunction in PD.

Introduction

Background: Cognitive dysfunction is one of the quintessential non-motor features of Parkinson's disease (PD)[1]. Using the conventional framework of cognitive impairment and dementia[2], cognitive dysfunction is twice as likely to occur in PD compared to the general population[3] and can be found in 25 to 30% of newly diagnosed patients[4] and up to 80% of patients after 20 years of disease duration[5]. Incidence, prevalence, and severity of cognitive impairment and dementia increase with advancing age and disease duration. Cognitive dysfunction in PD is one of the most prevalent and burdensome non-motor symptoms for patients and caregivers and is challenging for clinicians to manage[6]. Furthermore, cognitive dysfunction in PD occurs on a spectrum ranging from mild cognitive impairment (PD-MCI)[7, 8] to dementia (PD-D)[9, 10]. PD-MCI in early stages of disease is a predictor of development of PD-D later in the disease course[11, 12] and early mortality[13]. As for the neurobiological basis of cognitive dysfunction in PD[14], several risk factors or biomarkers have been associated with PD-MCI or PD-D, including male sex[15], orthostatic hypotension, glucocerebrosidase (GBA) mutation[16], triplications in the α-synuclein gene, and low amyloid-β42 in cerebrospinal fluid[17, 18]. However, no marker has been shown to accurately predict development of PD-MCI or PD-D. Cholinesterase inhibitors (donepezil and rivastigmine) and an N-Methyl-D-aspartate (NMDA) receptor antagonist (memantine) have been shown to provide modest symptomatic benefit in clinical trials and are available for clinical use, but there has not been a single successful disease modifying drug approved for slowing down or preventing cognitive decline in PD.

Current approaches of PD-MCI and PD-D classification for investigating and classifying cognitive dysfunction in PD[19] are inherently restricted by virtue of their limited analysis of the underlying neuropsychological data and the limited binary (yes/no) outcome measures. Consequently, such categorical schemas fail to capture the heterogeneity and the continuum of cognitive dysfunction in PD. To this end, there is a critical need for developing novel approaches to classifying cognitive dysfunction in PD by looking at cognitive dysfunction as a continuum to solidify the foundation of detailed subtyping of cognitive dysfunction in PD. This is needed to better counsel patients and families on likely disease progression, and to improve efficiency and accuracy of clinical trials.

In this paper, we first review the current PD-MCI and PD-D classification schemes, including their limitations with respect to interpretation of neuropsychological data, followed by review of Partially Ordered Set (POSET) modeling for interpreting neuropsychological data. We then apply the POSET modeling approach to the Parkinson Progression Marker Initiative (PPMI) data to illustrate a novel approach to studying cognitive dysfunction in PD.

PD-MCI and PD-D Approaches for Studying Cognitive Dysfunction in PD: Conceptually, Mild cognitive impairment (MCI) refers to a syndrome representing a stage between normal aging and dementia. Historically, MCI was defined in the context of describing stages of cognitive decline preceding Alzheimer's disease but subsequently has been broadly applied for other etiologies of cognitive decline including PD. Dementia generally refers to an advanced stage of cognitive impairment when cognitive decline has become severe enough to negatively impact social and/or occupational functioning and thus cause impairment in functional independence[20].

Per the International Parkinson and Movement Disorder Society PD Mild Cognitive Impairment Task Force diagnostic criteria[7], PD-MCI is a syndrome defined by 1) clinical, 2) cognitive, and 3) functional criteria. Specifically, 1) a diagnosis of PD must be established, followed by the presence of gradual subjective cognitive decline as reported by the patient or their caregivers or as observed by the clinician in the absence of confounding factors (e.g., delirium, major depression etc.) ; 2) cognitive decline is corroborated with objective cognitive deficits as shown by impaired performance on global cognitive screening tests (e.g., Montreal Cognitive Assessment) or limited neuropsychological battery (abbreviated assessment, level I) and/or full battery of neuropsychological testing (comprehensive assessment, level II) assessing five cognitive domains (attention and working memory, executive function, language, memory, and visuospatial function) ; and 3) cognitive decline and deficits are not sufficiently interfering with functional dependence in terms of activity of daily living. An optional subtype classification into single-domain vs multi-domain PD-MCI can also be made based on comprehensive assessment based on impairment on at least two neuropsychological tests in one domain versus at least one test in two or more domains, respectively. Of note, impairment on neuropsychological tests is defined variably, including non-exclusive options of 1) test performance by approximately 1 to 2 standard deviations below appropriate norms, 2) significant decline demonstrated on serial cognitive testing, or 3) significant decline from estimated premorbid levels of function.

Per the International Parkinson and Movement Disorder Society PD Task Force[10], PD-D can be defined as a dementia syndrome characterized by core features (group I)

of 1) established diagnosis of PD and 2) insidious onset and slow progression of cognitive decline from premorbid level, which is present in more than one cognitive domain on NP testing and severe enough to impair daily life (social, occupational, or personal care) independent of motor or other non-motor impairment of PD. This classification scheme defines two levels, that is probable PD-D and possible PD-D, based on the presence or absence of associated features in group II (typical versus atypical profile of cognitive deficits; at least one or no behavioral symptoms), group III (presence of co-morbid causes of cognitive impairment, unknown time interval between cognitive and motor symptoms), and group IV (presence of other causes of cognitive impairment).

Although the two classification schemes share several data elements in their approach of classifying the cognitive dysfunction in PD, a patient with cognitive impairment can only be classified as either having PD-MCI or PD-D (table 1), provided there are no other identified causes of the impairment (e.g., delirium, medication effects, etc.).

Limitations of PD-MCI and PD-D Approaches to Interpreting neuropsychological Data: A cognitive domain is a broadly defined area of cognition (e.g., memory, executive functioning) while specific cognitive functions are more narrowly defined aspects of ability[21]. For example, within the domain of memory, evaluators assess multiple discrete functions including encoding, free recall, and recognition discrimination. Neuropsychological tests tap into multiple cognitive functions across cognitive domains. One must be aware that although neuropsychological tests are categorized into domains based upon the primary function they are assessing, other cognitive functions are also affecting the overall test performance. The overlapping involvement of multiple

cognitive domains and functions on any given neuropsychological measure is difficult to minimize and can make it more challenging to understand the true meaning of test scores. Some neuropsychological tests, such as memory measures, produce multiple scores that reflect these different functions, but many tests only produce one total score. To complicate matters further, cognitive tests also tap into functions that may be classified under a different cognitive domain. Keeping with the example of memory testing, these measures will also reflect an individual's attention, executive functioning, and language or visuospatial abilities. In research, similar challenges can arise due to the necessity of strictly defined cognitive domains. In clinical practice, clinicians utilize more comprehensive test batteries to look for patterns within and across test domains to help clarify the meaning of test scores.

Interpretation and analysis of neuropsychological data using the PD-MCI and PD-D classification schemes presents a complex problem when describing cognitive impairment. As noted above, a problem in linking performance on a test item to distinguish impairment in a certain cognitive domain is that an item often requires engagement with more than one of the cognitive functions within that domain and may involve additional other functions to perform well. If a subject performs poorly on an item involving several cognitive functions, it can be unclear which of the involved functions may be impaired. Despite the wide variety of cognitive batteries available, clarifying specific deficits in cognitive domains is complicated by the challenge of effectively delineating which cognitive functions are required to perform on the test item mapped to that domain. Poor performance on a given task may stem from a variety of specific deficits, for instance, subpar performance on a verbal list-learning task may be

attributed to deficits in verbal fluency or due to impaired attention. These overlapping domains of cognitive impairment have been ineffectively addressed using subscales— an attempt to increase specificity in attribution of impaired functions to cognitive performance by ignoring the multi-faceted nature of tasks. Subscales rely on simplistic assumptions that there are one-to-one correspondences between a task and a specific function, which may obfuscate the true cognitive underpinnings of poor performance. In addition, reliance on total scores from expanded cognitive batteries presents similar issues. While the summed scores may indicate the presence or absence of cognitive deficits, it is possible to produce the same summed score from multiple iterations of responses and/or task performances, further obscuring the involvement or absence of specific deficits.

Partially Ordered Set (POSET) Modeling Approach to Interpreting neuropsychological Data: POSET models[22] serve as a basis for novel methods tailored for classifying the performance (functioning) levels of subjects with respect to specific cognitive functions[23, 24] and have been applied for predicting conversion from MCI to Alzheimer's disease[25-27] and distinguishing neurocognitive profiles in Schizophrenia[28]. POSET modeling addresses the above outlined limitations of current approaches to neuropsychological scoring. Classification is conducted based on observed responses to neuropsychological measures after each measure is associated with specific cognitive functions that are involved in performing well on that measure, so that the ties between observed responses and functioning levels are clear. This key step is conducted with expertise from a neuropsychologist, and validated data-analytically through assessing consistency of specifications to response data[29]. A

partially ordered set of possible profiles of performance (discrete levels, such as high or low) of each of the functions can be generated. Partial orders provide richness in modeling response data, and POSET models allow for one subject to have strengths that another subject does not, and vice versa. With each cognitive battery invoking multiple specific cognitive functions, and with varying ranges of performances, POSET models allow for a flexible partial ordering of responses informing complex profiles of cognitive strengths and weaknesses. Theoretical statistical properties support this approach[22], in that true latent profiles of mastery across cognitive functions will be correctly identified if the specifications are accurate, and enough task response data are observed.

As an illustration, the Category Fluency test involves the subject being asked to say all the words they can think of within a given semantic category, e.g., "vegetables." Some functions required for the test include verbal fluency, rapid word retrieval, semantic memory, and executive functions (e.g., cognitive flexibility, effective search patterns). If an individual performs poorly on the Category Fluency test but performed well on another test, e.g., Boston Naming, which involves visual confrontational naming, poor performance on Category Fluency might then be attributed in part to poor executive functions (e.g., cognitive flexibility, effective search patterns), and less a pure "language" problem. Of course, variability in response behavior and the test score values themselves must be considered when assessing the strength of this evidence. This is formalized in a statistical Bayesian framework. Importantly, this systematic approach can be extended to more complex scenarios, when there are multiple functions involved within and across measures. Thus, POSET modeling can manage

the aggregate response results and methodically classify cognitive profiles, mimicking the logic of a neuropsychologist's interpretation of confounded data.

Here, we provide proof-of-concept for application of the POSET modelling for delineating the heterogeneity and trajectory of cognitive dysfunction in PD using the Parkinson Progression Marker Initiative (PPMI) data.

Materials and Methods

From five neuropsychological tests available in the PPMI data, we first selected nine scores by either selecting sub scores or total score (eTable 1). The means and standard deviations of the original nine scores from the PPMI dataset are provided (eTable 2).

Based on the available tests and expert neuropsychologists' opinion, we grouped the PPMI data into five POSET models-based cognitive domains representing overlapping cognitive functions being assessed by the included scores from neuropsychological tests (irrespective of the traditional cognitive domains): 1) Attention (the ability to attend to the demands of the cognitive battery), 2) Visuospatial Functioning (the ability to accurately perceive and interact with visuospatial information), 3) Executive Functioning (higher level cognitive skills that help guide behavior, such as planning, problem-solving, and abstract thinking), 4) Working Memory (the ability to cognitively manipulate short-term memory) and 5) Episodic Memory (memory for recent or past events that involves encoding, storage, and retrieval of information). We then created corresponding Cognitive Performance Scores (CPS) by mapping these five domains onto selected scores (table 2) primarily based on the neuropsychologist's expert opinion

and then applying the POSET modeling. These individual CPS represent posterior probabilities of a subject's functioning in the corresponding cognitive domains at a high level, sufficient for performing well on the associated tasks, such that a lower value of CPS indicates a lower level of functioning relative to the other PD patients included in the sample. We derived additional mapping based on insights gained by analysis of statistical distributions of the related test scores and corresponding POSET models of fitness. For example, we mapped HVLT-R Recognition Discrimination Score to both Episodic Memory and Executive Functioning. Specifically, HVLT-R Recognition Discrimination Score and HVLT-R Delayed Recall Score were initially only mapped to Episodic Memory (and Attention). However, analysis of distributions of the HVLT-R Recognition Discrimination Score and HVLT-R Delayed Recall Score demonstrated that a small subset of patients can have differential impairment in the HVLT-R Recognition Discrimination despite normal HVLT-R Delayed Recall (eFigure 1-3). Accordingly, in consultation with neuropsychologist experts and corresponding POSET model fitness parameters, we additionally mapped HVLT-R Recognition Discrimination Score to Executive Functioning.

We used the data of 418 PD subjects in the PPMI database as of June 28th, 2023. Based on the conventional classification scheme of cognitive impairment used in PPMI, we categorized the PD patients to have cognitive dysfunction if they were labeled as having either mild cognitive impairment or dementia by the site investigator at year 3. We then selected data of 264 PD subjects by removing the PD subjects with cognitive dysfunction at baseline or with any missing neuropsychological data from baseline to year 3. Statistical analyses were performed using IBM SPSS Statistics for Macintosh,

Version 29.0.1.1. For summary statistics, we used mean and standard deviation for reporting the original neuropsychological scores, and median and interquartile range (IQR) for reporting the CPS given the skewed distribution of CPS (eFigure 4-8).

We also conducted a multivariate logistic regression to examine whether the five CPS at baseline would be predictive of cognitive dysfunction at year 3, with baseline age, gender, and education as covariates. Model fit statistics were calculated, and classification performance was evaluated. To further evaluate the discriminative ability of the multivariate logistic regression model in predicting cognitive dysfunction at year 3, we conducted a Receiver Operating Curve (ROC) analysis based on predicted probabilities from the model.

Results

The mean age was 61.16 years and there were 177 out of 264 males (67%) in the study cohort. The prevalence of cognitive dysfunction at year 3 was 56 out of 264 patients (21.2%), of which 51 patients had MCI, and 5 patients had dementia. The summary statistics (median and IQR) of the five CPS (Attention, Visuospatial Judgement, Executive Functioning, Working Memory, and Episodic Memory) across four visits (baseline, year 1, year 2, and year 3) for the 264 selected PD subjects and stratified by presence of absence of cognitive dysfunction at year 3 are provided (table 3).

Longitudinal trajectories of CPS medians showed clear delineations between patient groups stratified by presence or absence of cognitive dysfunction at year 3 (figure 1). Patients who were cognitively normal at year 3 ($n = 208$) demonstrated stable or slightly improved performance across all CPS over time. In contrast, patients with cognitive dysfunction at year 3 ($n = 56$) exhibited markedly different trajectories. Of note,

longitudinal trajectories of the medians of all five CPS were consistently and substantially lower for patients with cognitive dysfunction compared to patients without cognitive dysfunction or even when compared to all patients. Regarding distribution, there were significant differences between the two groups (p value < 0.05, Mann-Whitney test) for all five CPS at all four visits except for Episodic Memory at baseline (eTable 3-6).

From the multivariable logistic regression analysis, we found that baseline Attention CPS (p = 0.049) and Visuospatial Judgement CPS (p = 0.030) were significant predictors of cognitive dysfunction at year 3, such that lower baseline CPS in these two domains were associated with higher odds of cognitive dysfunction at year 3. Among the covariates, age at baseline was also a significant predictor ($p = 0.011$), while gender and education were not significant. From the ROC analysis, the area under the curve (AUC) was 0.782 with 95% confidence intervals (0.721, 0.843). A cutoff probability of 0.40 was identified based on ROC curve analysis as a threshold for classification, balancing sensitivity and specificity. The resultant sensitivity was 35.7% (20/56), and specificity was 91.3% (190/208). The p-value for Hosmer-Lemeshow test was > 0.05, suggesting adequate model fit.

Discussion

In this paper, we describe POSET modeling as a novel potential solution to address limitations of existing methods of delineating cognitive dysfunction and avoid false associations of the involvement of multiple cognitive domains. We have demonstrated proof of concept using the PPMI cohort with promising initial findings. Applying the

POSET models to larger and more robust datasets may hold the potential to not only redemonstrate known associations but also elucidate previously unknown factors in early PD that predict specific cognitive deficits later in the disease course.

POSET models-based approach for studying cognitive dysfunction results in development of "States" associated with profiles of cognitive domains that summarize performance levels for cognitive domains being tested by a given neuropsychological battery (figure 2). State 1 is the highest state in the POSET model, as it has the highest level of functioning for all five cognitive domains while state 16 is the lowest state, since functioning for all five domains is at the lowest level. For the in-between states, there exists at least one function for which performance is not at a relatively high level. The ordered relationships between states arise when identifying subgroups with shared functioning levels for a function. Once subgroups have been identified and classification conducted, the probability that a subject has a particular performance level for a function can be computed by summing the posterior probabilities of membership of each of the states in the subgroup.

Our results from using the PPMI study data indicate that lower baseline CPS in Attention and Visuospatial Judgement domains may be associated with increased risk of cognitive dysfunction at year 3 independent of baseline demographic variables. We note that the relatively low sensitivity rate indicates that the CPS are not sufficient alone for prediction. However, the high specificity and relatively high AUC value do indicate that these CPS provide useful predictive information.

Among other analytical approaches used in literature for predicting future cognitive dysfunction in PD, factor analysis has been the most widely used technique[30-33].

Specifically, factor analysis involves dimensionality reduction and to identify subscales that are comprised of linear combinations of weighted cognitive test scores. Potential issues with this approach include the lack of precise clarity in interpreting the practical meaning of the subscales from the relative weightings (factor loadings), and replicability of these factor loading values, especially given different rotational approaches on a same data set can provide different sets of loadings. More generally, note also that a subscale cannot recognize the polyfactorial nature of cognitive tests. Poor performance on a polyfactorial test necessarily penalizes all subscale score, even if the source of poor performance is due to impairment in involved function that is not associated with the subscale. Hence, subscale scores can be misleading. In contrast, POSET models explicitly recognize if a test is polyfactorial, and statistical convergence properties[22, 34] ensure efficient and accurate identification of cognitive function mastery profiles, so that interpretation is clear.

This approach for processing neuropsychological data is feasible as the POSET models have essential statistical convergence properties assuring that a subject's state is identified accurately with sufficient measurement, even in the presence of measures that are associated with multiple functions[22]. Furthermore, the POSET models explicitly link functions and measures and provide a means for data-analytic validation of these links[29]. Of note, other studies have also attempted to capture the richness of neuropsychological data into a single score for studying cognitive dysfunction in PD. Specifically, a recent study created a composite score by generating regression-based z scores for six cognitive tests for healthy controls participants without cognitive decline and then averaging all z scores for PD patients[35]. Notable effect sizes versus PD

patients were obtained from an enriched subgroup of healthy controls. In comparison, our Bayesian POSET models-based approach generates individual probabilities of mastery for specific functions that incorporate all associated tasks, recognizing the polyfactorial nature of tasks as opposed to enforcing a one-to-one association between a task and a domain[29]. Importantly, the POSET models here are developed using PD patients, so that differences and high performance are relative to those with PD. This enhances the sensitivity to detect differences within PD patients. Combining modeling with healthy controls can make it harder to detect more nuanced differences among PD patients.

Our proof-of-concept analyses using data from the PPMI study cohort demonstrate the feasibility of the application of the POSET models-based approach to modeling the heterogeneity and trajectories of cognitive dysfunction in PD. However, there are many limitations of this study, including lack of comprehensive assessment of cognitive dysfunction in the PPMI, a relatively short neuropsychological battery, and missing longitudinal data leading to the introduction of sampling bias. To overcome some of these limitations, we are currently implementing and evaluating the POSET models-based approach in a multi-center study, titled Cognitive Functions Impairment as a Novel Paradigm for Delineating Cognitive Dysfunction in Parkinson's Disease (PD-CFI)[36]. Specifically, we are using the data of the Pacific Northwest Udall Center of Excellence clinical consortium designed specifically for studying cognitive dysfunction in PD[37], expanded neuropsychological battery and criteria of the PD-MCI[7] and PD-D[10], comprehensive assessment of cognitive dysfunction involving consensus meetings among movement disorders neurologists and neuropsychologists, as well as

an informatics-based approach using a novel clinical decision support (CDS) platform for PD (CDS-PD)[38]. Another potential limitation of this study stems from the use of the PPMI-defined investigator diagnosis of cognitive state as the outcome variable (simplified as normal cognition, MCI, dementia) in that the site investigator diagnostic decision, while fundamentally a clinical diagnosis, may have been informed by neuropsychological tests used in the POSET models. This potential overlap could precipitate something of a circular approach wherein the neuropsychological tests used to map and generate the CPS may have also contributed to the ultimate clinical diagnosis of whether a subject had cognitive dysfunction. Ultimately, the site investigator's diagnosis is foremost a clinical diagnosis, and while neuropsychological measures may have been incorporated into the medical decision making, investigator diagnosis remains representative of the gold standard of a holistic clinical assessment.

Acknowledgements

We thank the PPMI – a public-private partnership – which is funded by the Michael J.

Fox Foundation for Parkinson's Research, and funding partners.

Funding

This study was funded by the project titled "Cognitive Functions Impairment as a Novel Paradigm for Delineating Cognitive Dysfunction in Parkinson's Disease (PD-CFI)", funded by the Investigator Initiative Research Award (IIRA) of the Parkinson Research Program (PRP) of the Congressionally Directed Medical Research Program (CDMRP) of the United States (US) Department of Defense (DOD). Award # HT94252310222

Conflict of Interest

None

Datasets/Data Availability Statement

Data used in the preparation of this article was obtained on [2023-06-28] from the

Parkinson's Progression Markers Initiative (PPMI) database (www.ppmi-

info.org/access-data-specimens/download-data), RRID:SCR_006431. For up-to-date

information on the study, visit www.ppmi-info.org.

The dataset used in this publication will be made available be made available by

request from any qualified investigator.

References

1. Weintraub, D. and D.J. Burn, *Parkinson's disease: the quintessential neuropsychiatric disorder.* Movement Disorders, 2011. **26**(6): p. 1022-1031.
2. Pagonabarraga, J. and J. Kulisevsky, *Cognitive impairment and dementia in Parkinson's disease.* Neurobiology of disease, 2012. **46**(3): p. 590-596.
3. Aarsland, D., et al., *Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.* neurology, 2009. **72**(13): p. 1121-1126.
4. Santangelo, G., et al., *Mild cognitive impairment in newly diagnosed Parkinson's disease: a longitudinal prospective study.* Parkinsonism & Related Disorders, 2015. **21**(10): p. 1219-1226.
5. Hely, M.A., et al., *The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.* Movement disorders, 2008. **23**(6): p. 837-844.
6. Halhouli, O., Q. Zhang, and G.M. Aldridge, *Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson's disease.* Progress in Brain Research, 2022. **269**(1): p. 407-434.
7. Litvan, I., et al., *Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.* Movement disorders, 2012. **27**(3): p. 349-356.
8. Goldman, J.G., et al., *Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.* Movement Disorders, 2018. **33**(4): p. 503-510.
9. Goetz, C.G., M. Emre, and B. Dubois, *Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.* Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 2008. **64**(S2): p. S81-S92.
10. Emre, M., et al., *Clinical diagnostic criteria for dementia associated with Parkinson's disease.* Movement disorders: official journal of the Movement Disorder Society, 2007. **22**(12): p. 1689-1707.
11. Hoogland, J., et al., *Mild cognitive impairment as a risk factor for Parkinson's disease dementia.* Movement Disorders, 2017. **32**(7): p. 1056-1065.
12. Pedersen, K.F., et al., *Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study.* JAMA neurology, 2013. **70**(5): p. 580-586.
13. Bäckström, D., et al., *Early predictors of mortality in parkinsonism and Parkinson disease: a population-based study.* Neurology, 2018. **91**(22): p. e2045-e2056.
14. Halliday, G.M., et al., *The neurobiological basis of cognitive impairment in Parkinson's disease.* Movement disorders, 2014. **29**(5): p. 634-650.
15. Cholerton, B., et al., *Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.* Parkinsonism & related disorders, 2018. **50**: p. 29-36.
16. Fagan, E. and L. Pihlstrøm, *Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature.* European Journal of Neurology, 2017. **24**(4): p. 561-e20.
17. Bäckström, D., et al., *Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study.* Brain communications, 2022. **4**(2): p. fcac040.
18. Gramotnev, D.K., et al., *Path analysis of biomarkers for cognitive decline in early Parkinson's disease.* Plos one, 2022. **17**(5): p. e0268379.
19. Weintraub, D., et al., *Initial cognitive changes in Parkinson's disease.* Movement Disorders, 2018. **33**(4): p. 511-519.
20. Hugo, J. and M. Ganguli, *Dementia and cognitive impairment: epidemiology, diagnosis, and treatment.* Clinics in geriatric medicine, 2014. **30**(3): p. 421-442.

21.   Harvey, P.D., *Domains of cognition and their assessment.* Dialogues in clinical neuroscience, 2022.

22.   Tatsuoka, C. and T. Ferguson, *Sequential classification on partially ordered sets.* Journal of the Royal Statistical Society: Series B (Statistical Methodology), 2003. **65**(1): p. 143-157.

23.   Tatsuoka, C., F. Varadi, and J. Jaeger, *Latent partially ordered classification models and normal mixtures.* Journal of Educational and Behavioral Statistics, 2013. **38**(3): p. 267-294.

24.   Honomichl, R.D., et al., *Identifying individual differences in adolescent neuropsychological function using the NIH Toolbox: An application of partially ordered classification modeling.* Neuropsychology, 2019. **33**(7): p. 996-1006.

25.   Hendrix, S.B. and K.A. Welsh-Bohmer, *Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease.* Alzheimer's Research & Therapy, 2013. **5**(3): p. 1-2.

26.   Carr, S.J., et al., *Associating cognition with amyloid status using partially ordered set analysis.* Frontiers in Neurology, 2019. **10**: p. 976.

27.   Tatsuoka, C., et al., *Modeling the heterogeneity in risk of progression to Alzheimer's disease acrosscognitive profiles in mild cognitive impairment.* Alzheimer's research & therapy, 2013. **5**(2): p. 1-19.

28.   Jaeger, J., et al., *Distinguishing neurocognitive functions in schizophrenia using partially ordered classification models.* Schizophrenia bulletin, 2006. **32**(4): p. 679-691.

29.   Tatsuoka, C., *Data analytic methods for latent partially ordered classification models.* Journal of the Royal Statistical Society: Series C (Applied Statistics), 2002. **51**(3): p. 337-350.

30.   Cholerton, B.A., et al., *Evaluation of mild cognitive impairment subtypes in Parkinson's disease.* Mov Disord, 2014. **29**(6): p. 756-64.

31.   Chung, S.J., et al., *Factor analysis-derived cognitive profile predicting early dementia conversion in PD.* Neurology, 2020. **95**(12): p. e1650-e1659.

32.   Chung, S.J., et al., *Baseline cognitive profile is closely associated with long-term motor prognosis in newly diagnosed Parkinson's disease.* J Neurol, 2021. **268**(11): p. 4203-4212.

33.   Young, C.B., et al., *The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.* Neurology, 2025. **104**(11): p. e213648.

34.   Tatsuoka, C., *Sequential classification on lattices with experiment-specific response distributions.* Sequential Analysis, 2014. **33**(3): p. 400-420.

35.   Weintraub, D., et al., *Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.* Movement Disorders, 2025.

36.   *Cognitive Functions Impairment as a Novel Paradigm for Delineating Cognitive Dysfunction in Parkinson's Disease (PD-CFI).* 2023; Available from: https://dtic.dimensions.ai/details/grant/grant.13858982?search_mode=content&search_text=Cognitive%20Functions%20Impairment%20as%20a%20Novel%20Paradigm%20for%20Delineating%20Cognitive%20Dysfunction%20in%20Parkinson%27s%20Disease%20(PD-CFI)%0A&search_type=kws&search_field=full_search.

37.   Cholerton, B.A., et al., *Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.* Journal of Parkinson's disease, 2013. **3**(2): p. 205-214.

38.   *Ontology-based, Real-time, Machine learning Informatics System for PD (ORMIS-PD).* 2021; Available from: https://dtic.dimensions.ai/details/grant/grant.9843089?search_mode=content&search_text=ormis-pd&search_type=kws&search_field=full_search.

Tables

Table 1: Comparing PD-MCI and PD-D Classification

Data Elements Description	PD-MCI Classification	PD-D Classification
Cognitive Symptoms Description	Presence of gradual subjective cognitive decline as reported by the patient or their caregivers or as observed by the clinician	Insidious onset and slow progression of cognitive decline from premorbid level
Minimum Numbers of Cognitive Domains Affected on Neuropsychological Testing	At least one domain	More than one domain
Impact of Cognitive Decline	Not sufficiently interfering with activities of daily living	Impairing daily life (social, occupational, or personal care)
Levels of Classification (Possible, Probable)	Based on screening versus comprehensive neuropsychological testing and extent of neuropsychological testing	Based on typical versus atypical profile of cognitive deficits, presence of behavioral symptoms and comorbid or other etiologies

Caption: Comparison of PD-MCI and PD-D classification schemes for describing cognitive dysfunction of a PD patient in mutually exclusive categories.

Table 2: Score Mapping to Cognitive Domains

Score	Attention	Visuospatial Judgement	Executive Functioning	Working Memory	Episodic Memory
Benton Judgement of Line Orientation	X	X			
HVLT Delayed Recall	X				X
HVLT Recognition Discrimination	X		X		X
HVLT Immediate Recall	X			X	
Letter Number Sequencing	X			X	
Semantic Fluency Animal Score	X		X		
Semantic Fluency Fruit Score	X		X		
Semantic Fluency Vegetable Score	X		X		
Symbol Digit Modality	X	X		X	

Caption: Mapping five individual Cognitive Domains to nine scores from the neuropsychological tests.

Table 3: Descriptive Statistics for CPS Stratified by Cognitive Dysfunction

Cognitive Performance Score (CPS)		Median (Interquartile Range)			
		Baseline	**Year 1**	**Year 2**	**Year 3**
Attention	CD = no	0.996 (0.070)	0.996 (0.101)	0.997 (0.107)	0.997 (0.093)
	CD = yes	0.844 (0.341)	0.850 (0.449)	0.728 (0.444)	0.752 (0.460)
	All Patients	0.991 (0.142)	0.991 (0.155)	0.992 (0.211)	0.992 (0.173)
Visuospatial Judgement	CD = no	0.499 (0.497)	0.479 (0.507)	0.494 (0.493)	0.495 (0.499)
	CD = yes	0.301 (0.210)	0.310 (0.210)	0.379 (0.208)	0.304 (0.209)
	All Patients	0.486 (0.501)	0.455 (0.494)	0.482 (0.481)	0.483 (0.497)
Executive Functioning	CD = no	0.748 (0.889)	0.812 (0.775)	0.826 (0.845)	0.797 (0.802)
	CD = yes	0.225 (0.746)	0.064 (0.760)	0.088 (0.887)	0.057 (0.436)
	All Patients	0.602 (0.914)	0.644 (0.898)	0.757 (0.913)	0.601 (0.906)
Working Memory	CD = no	0.702 (0.683)	0.698 (0.723)	0.567 (0.757)	0.678 (0.745)
	CD = yes	0.193 (0.653)	0.169 (0.504)	0.125 (0.313)	0.088 (0.497)
	All Patients	0.562 (0.747)	0.558 (0.758)	0.457 (0.763)	0.549 (0.815)
Episodic Memory	CD = no	0.408 (0.804)	0.449 (0.788)	0.710 (0.711)	0.476 (0.808)
	CD = yes	0.273 (0.495)	0.163 (0.271)	0.169 (0.344)	0.168 (0.164)
	All Patients	0.323 (0.780)	0.335 (0.766)	0.491 (0.801)	0.339 (0.801)

Caption: Median and IQR for the five CPS stratified by Cognitive Dysfunction (CD) and for all patients across four visits from baseline to year 3.

Figures

Figure 1: CPS Median Trajectories

Caption: Longitudinal trajectories of the median of the five Cognitive Performance Scores (CPS) across four visits, stratified by presence or absence of Cognitive Dysfunction at year 3, with the full cohort included for reference.

Figure 2: CPS POSET Model

Caption: POSET model for cognitive functioning of subjects in PPMI data with individual numbers representing "States" from the lowest: 16, to the highest: 1.